Matsuo T - Search Results

1

Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma.

Ando T, Kudo Y, Iizuka S, Tsunematsu T, Umehara H, Shrestha M, Matsuo T, Kubo T, Shimose S, Arihiro K, Ogawa I, Ochi M, Takata T. Ando T, et al. Among authors: matsuo t. Sci Rep. 2017 Jan 5;7:40187. doi: 10.1038/srep40187. Sci Rep. 2017. PMID: 28054649 Free PMC article.

2

Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.

Kubo T, Shimose S, Matsuo T, Tanaka K, Yasunaga Y, Sakai A, Ochi M. Kubo T, et al. Among authors: matsuo t. J Orthop Res. 2006 Jun;24(6):1138-44. doi: 10.1002/jor.20177. J Orthop Res. 2006. PMID: 16705696 Free article.

3

Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.

Kubo T, Shimose S, Matsuo T, Sakai A, Ochi M. Kubo T, et al. Among authors: matsuo t. Cancer Chemother Pharmacol. 2008 Jun;62(1):111-6. doi: 10.1007/s00280-007-0580-y. Epub 2007 Sep 15. Cancer Chemother Pharmacol. 2008. PMID: 17874104

4

Interferon-α/β receptor as a prognostic marker in osteosarcoma.

Kubo T, Shimose S, Matsuo T, Fujimori J, Arihiro K, Ochi M. Kubo T, et al. Among authors: matsuo t. J Bone Joint Surg Am. 2011 Mar 16;93(6):519-26. doi: 10.2106/JBJS.J.00198. J Bone Joint Surg Am. 2011. PMID: 21411701 Clinical Trial.

5

Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines.

Fujimori J, Matsuo T, Shimose S, Kubo T, Ishikawa M, Yasunaga Y, Ochi M. Fujimori J, et al. Among authors: matsuo t. J Orthop Res. 2011 Nov;29(11):1707-11. doi: 10.1002/jor.21451. Epub 2011 May 16. J Orthop Res. 2011. PMID: 21590716 Free article.

6

Clinical outcomes of 54 pelvic osteosarcomas registered by Japanese musculoskeletal oncology group.

Matsuo T, Sugita T, Sato K, Hotta T, Tsuchiya H, Shimose S, Kubo T, Ochi M. Matsuo T, et al. Oncology. 2005;68(4-6):375-81. doi: 10.1159/000086978. Epub 2005 Jul 12. Oncology. 2005. PMID: 16020966

7

Scalp metastasis from malignant fibrous histiocytoma of bone.

Kubo T, Shimose S, Matsuo T, Arihiro K, Ochi M. Kubo T, et al. Among authors: matsuo t. J Am Acad Dermatol. 2008 Nov;59(5 Suppl):S88-91. doi: 10.1016/j.jaad.2008.06.039. J Am Acad Dermatol. 2008. PMID: 19119134

8

Extraskeletal osteosarcoma with partial spontaneous regression.

Matsuo T, Shimose S, Kubo T, Mikami Y, Arihiro K, Yasunaga Y, Ochi M. Matsuo T, et al. Anticancer Res. 2009 Dec;29(12):5197-201. Anticancer Res. 2009. PMID: 20044636 Free article.

9

Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.

Kubo T, Shimose S, Matsuo T, Fujimori J, Sakaguchi T, Yamaki M, Shinozaki K, Woo SL, Ochi M. Kubo T, et al. Among authors: matsuo t. J Orthop Res. 2011 May;29(5):795-800. doi: 10.1002/jor.21307. Epub 2010 Dec 17. J Orthop Res. 2011. PMID: 21437961 Free article.

10

Postradiation malignant fibrous histiocytoma and osteosarcoma of a patient with high telomerase activities.

Matsuo T, Sugita T, Shimose S, Kubo T, Yasunaga Y, Hiyama E, Ochi M. Matsuo T, et al. Anticancer Res. 2005 Jul-Aug;25(4):2951-5. Anticancer Res. 2005. PMID: 16080549 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,870 results

Search Page